Anti-LL-37

LL-37 is a cationic alpha-helical peptide expressed in human bone marrow, testis, granulocytes, gingival epithelium, and a variety of immune cells. It is produced by proteolytic cleavage of the cathelicidin human cationic antimicrobial protein of 18 kDa (hCAP18). LL-37 has antimicrobial and antiviral activity, and protein levels of LL-37 are increased in epithelial cells, macrophages, and neutrophils following bacterial infection in vitro. It functions as a chemoattractant for human monocytes, neutrophils, and T cells, and induces chemokine secretion from epithelial cells in infected tissues. LL-37 is a component of LPS-induced NETs produced from human neutrophils isolated from patients with systemic lupus erythrematosus (SLE) or individuals without SLE. It also enhances PMA- or S. aureus-induced formation of NETs. LL-37 can be citrullinated by protein arginine deiminase 2 (PAD2) and PAD4, a modification that reduces its antibacterial and antiviral activities. Native, but not citrullinated, LL-37 prevents mortality in a mouse model of D-galactosamine-sensitized endotoxic shock. Cayman's LL-37 Polyclonal Antibody can be used for Western blot.Synonyms: Antibacterial Protein LL-37. Immunogen: Synthetic human LL-37. Formulation: (Request formulation change), 500 µl of peptide affinity-purified polyclonal antibody. Storage Buffer: TBS, pH 7.4, conaining 50% glycerol, 0.1% BSA, and 0.02% sodium azide. Host: Rabbit. Applications: WB. Cross Reactivity: (+) hCAP18, () LL-37. UniProt Accession #: P49913.